Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
SCPH Stock Summary
Top 10 Correlated ETFs
SCPH
In the News
scPharmaceuticals Inc (SCPH) Q4 2023 Earnings Call Transcript
scPharmaceuticals Inc (SCPH) Q4 2023 Earnings Call Transcript
scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024
BURLINGTON, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m.
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
BURLINGTON, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will participate in two upcoming investor conferences.
scPharmaceuticals Q3 Earnings: Cruising Toward Success
Q3 earnings report shows positive performance, with Furoscix net sales exceeding consensus estimates. scPharmaceuticals' progress in securing payer coverage and IDN agreements is driving confidence in its prospects. The company's healthy financial position and potential market opportunity for Furoscix make it an undervalued investment.
Short squeeze alert for November 9th: 2 stocks that could surge
Among various strategies and methods used in stock trading, shorting is a daring one. Seen as a high-risk approach, it involves borrowing and selling stocks, betting on their price decline.
scPharmaceuticals Inc (SCPH) Q3 2023 Earnings Call Transcript
scPharmaceuticals Inc (NASDAQ:SCPH ) Q3 2023 Earnings Call Transcript November 8, 2023 4:30 PM ET Company Participants PJ Kelleher - LifeSci Advisors John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President, Commercial Rachael Nokes - Chief Financial Officer Conference Call Participants Nik Gasic - Leerink Partners Douglas Tsao - H.C. Wainwright Naz Rahman - Maxim Group Chase Knickerbocker - Craig-Hallum Capital Group Operator Thank you for standing by.
scPharmaceuticals to Participate in Two Upcoming Investor Conferences
BURLINGTON, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, will participate in two upcoming investor conferences.
scPharmaceuticals: Furoscix, Charting A Bright Future With FDA's Nod For CKD
Positive FDA feedback for Furoscix's label expansion into chronic kidney disease signals the potential for significant market growth. Introduction of a higher concentration auto-injector formulation of Furoscix could reduce costs and enhance patient convenience. Q2 earnings show encouraging market momentum for Furoscix, with continued demand and growth in prescribers.
Sizing Up scPharmaceuticals
Today, we take our first look at scPharmaceuticals Inc., which has received positive analyst commentary but has a large short position in the stock. The company just launched its franchise product FUROSCIX in February of this year and management believes it has huge potential. Analysts expect sales to reach nearly $40 million in FY2024, but the company is projected to continue experiencing losses.
scPharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
BURLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference on Wednesday, September 13 at 10:00 am ET. In addition to the fireside chat, Mr. Tucker will also be meeting with investors.
SCPH Financial details
SCPH Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0.35 | |
Net income per share | -1.85 | -1.4 | -1.11 | -1.32 | -1.42 | |
Operating cash flow per share | -1.64 | -1.13 | -0.99 | -1.22 | -1.54 | |
Free cash flow per share | -1.64 | -1.13 | -0.99 | -1.22 | -1.54 | |
Cash per share | 3.91 | 5.64 | 2.75 | 4.17 | 1.97 | |
Book value per share | -6.96 | -6.58 | -6.94 | -7.99 | 0.97 | |
Tangible book value per share | 2.76 | 3.34 | 2.06 | 2.55 | 0.97 | |
Share holders equity per share | -6.96 | -6.58 | -6.94 | -7.99 | 0.97 | |
Interest debt per share | 1.18 | 0.93 | 0.74 | 1.43 | 1.22 | |
Market cap | 105.28M | 129.97M | 137.31M | 203.33M | 241.48M | |
Enterprise value | 52.74M | 44.9M | 80.67M | 169.64M | 234.94M | |
P/E ratio | -3.06 | -3.78 | -4.5 | -5.42 | -4.41 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 17.77 | |
POCF ratio | -3.46 | -4.69 | -5.06 | -5.88 | -4.08 | |
PFCF ratio | -3.46 | -4.69 | -5.06 | -5.88 | -4.07 | |
P/B Ratio | -0.81 | -0.8 | -0.72 | -0.9 | 6.49 | |
PTB ratio | -0.81 | -0.8 | -0.72 | -0.9 | 6.49 | |
EV to sales | 0 | 0 | 0 | 0 | 17.28 | |
Enterprise value over EBITDA | -1.69 | -1.52 | -3.17 | -5.06 | -4.29 | |
EV to operating cash flow | -1.73 | -1.62 | -2.97 | -4.91 | -3.97 | |
EV to free cash flow | -1.73 | -1.62 | -2.97 | -4.9 | -3.96 | |
Earnings yield | -0.33 | -0.26 | -0.22 | -0.18 | -0.23 | |
Free cash flow yield | -0.29 | -0.21 | -0.2 | -0.17 | -0.25 | |
Debt to equity | -0.16 | -0.12 | -0.09 | -0.16 | 1.05 | |
Debt to assets | 0.26 | 0.19 | 0.22 | 0.3 | 0.41 | |
Net debt to EBITDA | 1.68 | 2.87 | 2.22 | 1 | 0.12 | |
Current ratio | 14.44 | 11.57 | 5.27 | 16.63 | 7.08 | |
Interest coverage | -18.62 | -11.57 | -10.03 | -10.95 | -6.82 | |
Income quality | 0.92 | 0.86 | 0.97 | 0.94 | 1.08 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 3.93 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0.87 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | -0.02 | -0.04 | -0.06 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0.36 | |
Graham number | 17.02 | 14.4 | 13.19 | 15.42 | 5.56 | |
ROIC | 0.32 | 0.23 | 0.16 | 0.2 | -0.71 | |
Return on tangible assets | -0.45 | -0.32 | -0.39 | -0.3 | -0.58 | |
Graham Net | 2.6 | 4.55 | 1.93 | 2.42 | 0.69 | |
Working capital | 70.41M | 98.51M | 63.43M | 115.89M | 79.8M | |
Tangible asset value | 51.37M | 82.17M | 56.47M | 72.43M | 37.22M | |
Net current asset value | 49.73M | 80.95M | 55.71M | 71.55M | 35.68M | |
Invested capital | -0.16 | -0.12 | -0.09 | -0.16 | 1.05 | |
Average receivables | 394.5K | 155K | 0 | 1.14M | 3.39M | |
Average payables | 864.5K | 1.4M | 1.11M | 1.03M | 2.76M | |
Average inventory | 2.01M | 1.22M | 0 | 615K | 5.04M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 120.54 | |
Days payables outstanding | 1.15K | 1.52K | 453.33 | 1.18K | 383.2 | |
Days of inventory on hand | 2.44K | 0 | 0 | 959.29 | 846.65 | |
Receivables turnover | 0 | 0 | 0 | 0 | 3.03 | |
Payables turnover | 0.32 | 0.24 | 0.81 | 0.31 | 0.95 | |
Inventory turnover | 0.15 | 0 | 0 | 0.38 | 0.43 | |
ROE | 0.27 | 0.21 | 0.16 | 0.17 | -1.47 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0.05 | 0.04 | 0.1 | 0.16 | |
Net income per share | -0.31 | -0.34 | -0.37 | -0.4 | -0.36 | |
Operating cash flow per share | -0.38 | -0.44 | -0.37 | -0.35 | -0.39 | |
Free cash flow per share | -0.38 | -0.44 | -0.37 | -0.35 | -0.39 | |
Cash per share | 3.78 | 3.07 | 2.66 | 2.33 | 1.96 | |
Book value per share | -7.25 | -6.29 | -6.51 | 1.27 | 0.96 | |
Tangible book value per share | 2.32 | 2.01 | 1.64 | 1.27 | 0.96 | |
Share holders equity per share | -7.25 | -6.29 | -6.51 | 1.27 | 0.96 | |
Interest debt per share | 1.26 | 1.05 | 1.03 | 0.97 | 1.06 | |
Market cap | 224.09M | 342.85M | 394.28M | 275.98M | 243.19M | |
Enterprise value | 190.4M | 305.08M | 360.94M | 280.75M | 236.65M | |
P/E ratio | -5.74 | -6.68 | -6.96 | -4.41 | -4.4 | |
Price to sales ratio | 0 | 166.19 | 240.71 | 72.7 | 39.89 | |
POCF ratio | -18.93 | -20.79 | -27.88 | -20.52 | -16.04 | |
PFCF ratio | -18.92 | -20.79 | -27.88 | -20.52 | -16 | |
P/B Ratio | -0.99 | -1.44 | -1.57 | 5.62 | 6.53 | |
PTB ratio | -0.99 | -1.44 | -1.57 | 5.62 | 6.53 | |
EV to sales | 0 | 147.88 | 220.35 | 73.96 | 38.82 | |
Enterprise value over EBITDA | -26.12 | -32.98 | -29.72 | -18.92 | -15.65 | |
EV to operating cash flow | -16.08 | -18.5 | -25.52 | -20.87 | -15.61 | |
EV to free cash flow | -16.08 | -18.5 | -25.52 | -20.87 | -15.57 | |
Earnings yield | -0.04 | -0.04 | -0.04 | -0.06 | -0.06 | |
Free cash flow yield | -0.05 | -0.05 | -0.04 | -0.05 | -0.06 | |
Debt to equity | -0.16 | -0.16 | -0.15 | 0.81 | 1.05 | |
Debt to assets | 0.3 | 0.3 | 0.33 | 0.38 | 0.41 | |
Net debt to EBITDA | 4.62 | 4.08 | 2.75 | -0.32 | 0.43 | |
Current ratio | 16.63 | 16.38 | 17.12 | 9.53 | 7.08 | |
Interest coverage | -4.85 | -5.89 | -6.84 | 7.2 | -7.29 | |
Income quality | 1.28 | 1.47 | 1 | 0.86 | 1.1 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.01 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 5.28 | 7.38 | 0 | 0 | |
Research and developement to revenue | 0 | 1.03 | 1.79 | 0.9 | 0.55 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | -0.01 | |
Capex to depreciation | -0.05 | 0 | -0.03 | 0 | -0.26 | |
Stock based compensation to revenue | 0 | 0.48 | 0.72 | 0.34 | 0.23 | |
Graham number | 7.14 | 6.93 | 7.32 | 3.39 | 2.77 | |
ROIC | 0.05 | 0.07 | 0.07 | -0.16 | -0.2 | |
Return on tangible assets | -0.08 | -0.1 | -0.12 | -0.15 | -0.15 | |
Graham Net | 2.2 | 1.81 | 1.45 | 1.03 | 0.68 | |
Working capital | 115.89M | 118.93M | 106.94M | 93.39M | 79.8M | |
Tangible asset value | 72.43M | 75.81M | 63.43M | 49.15M | 37.22M | |
Net current asset value | 71.55M | 75.1M | 62.83M | 47.38M | 35.68M | |
Invested capital | -0.16 | -0.16 | -0.15 | 0.81 | 1.05 | |
Average receivables | 1.14M | 2.64M | 2.31M | 2.89M | 4.33M | |
Average payables | 1.26M | 1.57M | 1.4M | 2.28M | 3.69M | |
Average inventory | 615K | 2.43M | 4.73M | 6.48M | 7.98M | |
Days sales outstanding | 0 | 131.05 | 88.46 | 98.99 | 66.27 | |
Days payables outstanding | 1.14K | 241.88 | 300.51 | 281.09 | 203.1 | |
Days of inventory on hand | 922.5 | 538.66 | 1.48K | 594.13 | 448.73 | |
Receivables turnover | 0 | 0.69 | 1.02 | 0.91 | 1.36 | |
Payables turnover | 0.08 | 0.37 | 0.3 | 0.32 | 0.44 | |
Inventory turnover | 0.1 | 0.17 | 0.06 | 0.15 | 0.2 | |
ROE | 0.04 | 0.05 | 0.06 | -0.32 | -0.37 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
SCPH Frequently Asked Questions
What is scPharmaceuticals Inc. stock symbol ?
scPharmaceuticals Inc. is a US stock , located in Burlington of Ma and trading under the symbol SCPH
What is scPharmaceuticals Inc. stock quote today ?
scPharmaceuticals Inc. stock price is $5.02 today.
Is scPharmaceuticals Inc. stock public?
Yes, scPharmaceuticals Inc. is a publicly traded company.